The global In Vivo Pharmacology market size is predicted to grow from US$ 4487 million in 2025 to US$ 6334 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.

In vivo pharmacology is a branch of pharmacology that focuses on the study of the effects, mechanisms of action, and safety of drugs and pharmaceutical compounds within living organisms. This field involves conducting experiments and tests on whole living organisms, such as animals (commonly rodents like mice and rats) and, in some cases, humans, to assess the pharmacological properties of drugs. In vivo studies are essential for understanding how drugs interact with biological systems, including their absorption, distribution, metabolism, and excretion (ADME), as well as their therapeutic effects and potential side effects.

Increasing Drug Development Activities: The pharmaceutical and biotechnology industries continue to expand, leading to increased demand for in vivo pharmacology services. Companies are actively developing new drugs, including those for complex diseases like cancer, autoimmune disorders, and neurodegenerative conditions, which often require extensive preclinical testing.

Increased Regulatory Scrutiny: Regulatory agencies, like the U.S. FDA and the European Medicines Agency, are continuously raising the bar for drug safety and efficacy. This has led to stricter requirements for preclinical testing, including more comprehensive and sophisticated in vivo studies.

Advancements in Animal Models: The development of more sophisticated and relevant animal models, including genetically engineered mice and patient-derived xenograft models, has enhanced the accuracy and predictive value of in vivo pharmacology studies.

Outsourcing and CRO Services: Many pharmaceutical companies are outsourcing their in vivo pharmacology studies to contract research organizations (CROs) to gain cost-efficiency, access specialized expertise, and meet timelines. This trend is expected to continue.

LPI (LP Information) newest research report, the ?In Vivo Pharmacology Industry Forecast? looks at past sales and reviews total world In Vivo Pharmacology sales in 2024, providing a comprehensive analysis by region and market sector of projected In Vivo Pharmacology sales for 2025 through 2031. With In Vivo Pharmacology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Vivo Pharmacology industry.

This Insight Report provides a comprehensive analysis of the global In Vivo Pharmacology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on In Vivo Pharmacology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global In Vivo Pharmacology market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Vivo Pharmacology and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Vivo Pharmacology.

This report presents a comprehensive overview, market shares, and growth opportunities of In Vivo Pharmacology market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Animal Disease Models
    Ex Vivo Pharmacology & Biomarkers
    PD/PK
    Others

Segmentation by Application:

    Ncology/Immuno-oncology
    Metabolic Disorders
    Inflammatory Diseases
    CNS Diseases

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Charles River
    The Jackson Laboratory
    Syngene
    Evotec
    Pharmaron
    Aurigene Pharmaceutical
    Jubilant Biosys
    Labcorp
    Inotiv
    Takeda Pharmaceutical
    EXUMA Biotech
    Novartis
    Be Biopharma
    Alderley Oncology
    Sygnature Discovery
    GenScript ProBio
    Zai Lab
    Sinclair Research
    Eli Lilly
    Gubra